uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2011 (English)In: JN. Journal of Nephrology (Milano. 1992), ISSN 1121-8428, Vol. 24, no 5, 589-596 p.Article in journal (Refereed) Published
Abstract [en]

Background: Patients with chronic kidney disease (CKD) often suffer from iron deficiency anemia necessitating treatment with intravenous iron. This study was designed to assess the safety of iron isomaltoside 1000 (Monofer) in CKD patients. The secondary objective was to assess its effect on iron deficiency anemia. Methods: This open-label, noncomparative, multi-center trial assigned 182 patients with CKD (n=161 in dialysis and n=21 in predialysis) to iron isomaltoside 1000 either as 4 intravenous bolus injections of 100-200 mg iron per dose or as a fast high-dose infusion at baseline. Patients were generally undergoing erythropoiesis-stimulating agent (ESA) treatment (82%), and the dosage was to be kept constant during the trial. They were either switched from an existing parenteral maintenance therapy (n=144) or were not currently being treated with parenteral iron (n=38). Frequency of adverse events (AEs) and changes in markers of iron deficiency anemia were measured during 8 weeks from baseline. Results: Nineteen treatment-related AEs occurred in 13 patients (7.1%) and after 584 treatments (3.3%). No anaphylactic or delayed allergic reactions were observed. There were no clinically significant changes in routine clinical laboratory tests or vital signs. Hemoglobin increased from 99.2 g/L (SD=9.0) at baseline to 111.2 g/L (SD=14.7) at week 8 in patients not currently treated with parenteral iron (p<0.001) and increased slightly or stabilized in patients in maintenance therapy. S-Ferritin, s-iron and transferrin saturation increased significantly at all visits. Conclusions: Iron isomaltoside 1000 was clinically well tolerated, safe and effective. This new intravenous iron may offer a further valuable choice in treating the anemia of CKD.

Place, publisher, year, edition, pages
2011. Vol. 24, no 5, 589-596 p.
Keyword [en]
Anemia, Chronic kidney disease, Intravenous iron treatment, Iron deficiency
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-164446DOI: 10.5301/JN.2010.6248ISI: 000296976000008OAI: oai:DiVA.org:uu-164446DiVA: diva2:468103
Available from: 2011-12-20 Created: 2011-12-20 Last updated: 2011-12-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wikström, Björn
By organisation
Department of Medical Sciences
In the same journal
JN. Journal of Nephrology (Milano. 1992)
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 191 hits
ReferencesLink to record
Permanent link

Direct link